Compare Abeona Therapeutics Inc (ABEO) vs Monolithic Power Systems Inc (MPWR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Monolithic Power Systems Inc — how do they compare? Abeona Therapeutics Inc trades at $7.38 (market cap $421.19M), while Monolithic Power Systems Inc trades at $1,434.83 (market cap $68.90B). The key difference: Monolithic Power Systems Inc is far larger — about 163.6× Abeona Therapeutics Inc's market cap, and Monolithic Power Systems Inc pays a 0.57% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | MPWR | |
|---|---|---|
Market Cap | $421.19M | $68.90B |
Sector | Health | Utilities |
52-Week High | $7.45 | $1.69K |
52-Week Low | $4.17 | $820.74 |
Enterprise Value | $276.10M | $67.51B |
Dividend Yield | — | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.
The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.
MPWR is trading at $1,446.91, up 4.77% in the last 24 hours, with a bullish technical signal and strong earnings momentum after beating Q2 2026 estimates. The stock shows robust fundamentals with a 24.5% net income margin and 21.98% ROE, though valuation ratios like P/E of 85.55 are elevated. Recent news highlights AI-driven revenue growth and a legal investigation into potential misleading statements.
The outlook is positive with an 88% analyst buy rating and a $1,870 consensus price target, but risks include high valuation sensitivity, competitive pressures, and legal scrutiny. Earnings growth from AI infrastructure demand remains a key catalyst for upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Monolithic Power Systems Inc
Monolithic Power Systems, Inc. is a global leader in high-performance, analog, and mixed-signal semiconductors. The company specializes in power management solutions, providing integrated circuits (ICs) for a wide range of applications, including computing, automotive, industrial, and communications. MPWR's proprietary process technology is designed to deliver highly energy-efficient and compact power solutions, positioning the company as a key supplier for the next generation of electronic devices.
Read more on MPWR →
